Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07315113 · ClinicalTrials.gov registry record · Phase 1
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A Phase 1 study of EGFR Mutation Positive Non-small Cell Lung Cancer and EGFR Mutated Non-small Cell Lung Cancer Patients, sponsored by Nuvectis Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT07315113 is a Phase 1 study of EGFR Mutation Positive Non-small Cell Lung Cancer and EGFR Mutated Non-small Cell Lung Cancer Patients that is actively recruiting participants, run by Nuvectis Pharma. The registered enrollment target is 18 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07315113, a Phase 1 study of EGFR Mutation Positive Non-small Cell Lung Cancer and EGFR Mutated Non-small Cell Lung Cancer Patients, is actively recruiting participants, sponsored by Nuvectis Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG NXP900
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- NEXT Houston - Houston
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07315113
The ClinicalTrials.gov registry entry for NCT07315113 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuvectis Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with EGFR Mutation Positive Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT07315113 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07315113 about?
NCT07315113 is a clinical study titled "Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer". This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
What is the current status of trial NCT07315113?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-12-18. Estimated completion is 2027-06.
What conditions does trial NCT07315113 study?
This clinical trial studies the following conditions: EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients.
What interventions are being tested in trial NCT07315113?
The interventions under investigation include: Osimertinib (DRUG), NXP900 (DRUG).
Who is sponsoring clinical trial NCT07315113?
This trial is sponsored by Nuvectis Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07315113 being conducted?
This trial has 3 study locations across Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
EGFR Mutation Positive Non-small Cell Lung Cancer
All registered trials for this condition
EGFR Mutated Non-small Cell Lung Cancer Patients
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.